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Abstract
Infections by the opportunistic fungal pathogen Candida albicans are widely treated with the antifungal agent fluconazole that inhibits the
biosynthesis of ergosterol, the major sterol in the fungal plasma membrane. The emergence of fluconazole-resistant C. albicans strains is a
significant problem after long-term treatment of recurrent oropharyngeal candidiasis (OPC) in acquired immunodeficiency syndrome (AIDS)
patients. Resistance can be caused by alterations in sterol biosynthesis, by mutations in the drug target enzyme, sterol 14a-demethylase
(14DM), which lower its affinity for fluconazole, by increased expression of the ERG11 gene encoding 14DM, or by overexpression of genes
coding for membrane transport proteins of the ABC transporter (CDR1/CDR2) or the major facilitator (MDR1) superfamilies. Different
mechanisms are frequently combined to result in a stepwise development of fluconazole resistance over time. The MDR1 gene is not or
barely transcribed during growth in vitro in fluconazole-susceptible C. albicans strains, but overexpressed in many fluconazole-resistant
clinical isolates, resulting in reduced intracellular fluconazole accumulation. The activation of the gene in resistant isolates is caused by
mutations in as yet unknown trans-regulatory factors, and the resulting constitutive high level of MDR1 expression causes resistance to other
toxic compounds in addition to fluconazole. Disruption of both alleles of the MDR1 gene in resistant C. albicans isolates abolishes their
resistance to these drugs, providing genetic evidence that MDR1 mediates multidrug resistance in C. albicans. D 2002 Elsevier Science B.V.
All rights reserved.
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1. Introduction
The yeast Candida albicans is a harmless colonizer of
mucosal surfaces in many healthy persons, but it can cause
superficial as well as life-threatening systemic infections in
immunocompromised patients. Especially people infected
with the human immunodeficiency virus (HIV) and
acquired immunodeficiency syndrome (AIDS) patients fre-
quently suffer from oropharyngeal candidiasis (OPC). Few
classes of antifungal drugs are available to treat Candida
infections. The azoles affect the biosynthesis of ergosterol,
the major sterol in the fungal plasma membrane, by inhibit-
ing the enzyme sterol 14a-demethylase (14DM), a cyto-
chrome P-450 enzyme. This key enzyme in the ergosterol
biosynthesis pathway catalyzes the oxidative removal of the
14a-methyl group from lanosterol. Azoles bind to the heme
in the active site of 14DM, competing with substrate bind-
ing [1]. The triazole fluconazole is the most widely used
drug to treat Candida infections, due to its favourable
bioavailability and safety profile. The clinical response to
fluconazole in patients with OPC is usually good but
because of incomplete eradication of the fungi due to the
fungistatic rather than fungicidal effect of azoles, relapses
occur frequently [2]. The prolonged and repeated treatment
of OPC in AIDS patients has resulted in an increasing
frequency of therapy failures caused by the emergence of
fluconazole-resistant C. albicans strains [3].
2. The development of fluconazole resistance in C.
albicans
Especially in AIDS patients receiving long-term fluco-
nazole therapy, clinical resistance is usually correlated with
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the isolation of C. albicans strains displaying decreased in
vitro susceptibility to fluconazole [3,4]. To determine
whether fluconazole resistance is due to the aquisition of a
new, resistant strain that replaces a previously infecting,
susceptible strain, or if resistance has developed in a
previously susceptible strain that colonized the patient
before, it is necessary to discriminate genetically unrelated
C. albicans strains from each other. Many molecular typing
methods are available for C. albicans, but Southern hybrid-
ization of genomic DNA with moderately repetitive DNA
elements has been shown to have the highest reproducibility
and discriminatory power (see Fig. 1). Molecular typing has
demonstrated that colonizing populations of C. albicans are
usually clonal, i.e. a single strain is in most cases the cause
of recurrent infections in a patient, but the strain may evolve
into subtypes [5]. However, it has also been shown that a
patient can be colonized by several different C. albicans
strains at the same time [6–8]. In many studies, only a
single isolate is characterized from each infection episode.
Therefore, a strain that was present as a minor constituent of
the colonizing population in the patient may be isolated for
the first time after it has acquired resistance and overgrown
a previously dominating other strain, thereby giving the
appearance of resistance being due to strain replacement.
Although transmission of a resistant strain, for example
from the sexual partner, may occur [9], the analysis of many
C. albicans isolates from patients with recurrent infections
has demonstrated that fluconazole resistance usually devel-
oped in a previously susceptible strain from the same patient
[10,11]. Such series of matched isolates, i.e. isolates repre-
senting the same C. albicans strain but differing in their
susceptibility to fluconazole, are an excellent tool to study
the mechanisms of drug resistance, since genetic alterations
in a resistant isolate as compared to a matched susceptible
isolate are likely to be related to the resistant phenotype [4].
3. The molecular mechanisms of fluconazole resistance
in C. albicans
Several different mechanisms may be responsible for the
development of fluconazole resistance in C. albicans. These
include alterations in the sterol biosynthesis pathway, over-
expression of the ERG11 gene encoding the drug target
enzyme 14DM, mutations in the ERG11 gene which result
in reduced affinity of 14DM to fluconazole, and reduced
intracellular drug accumulation, which is correlated with the
overexpression of membrane transport proteins. In contrast,
inactivation of the drug, a frequent cause of resistance to
antibiotics in bacteria, has not been described as a resistance
mechanism in C. albicans. The following sections summa-
rize the genetic evidence that is available for the involve-
ment of the various mechanisms in fluconazole resistance.
3.1. Alterations in the sterol biosynthesis pathway
Inhibition of 14DM by fluconazole not only results in
ergosterol depletion but also in the accumulation of the
methylated sterol 14a-methylergosta-8,24(28)-dien-3h,6a-
diol, which inhibits cell growth [12]. Alterations in the
sterol biosynthesis pathway that avoid the accumulation of
this growth inhibiting sterol in the presence of fluconazole
can cause fluconazole resistance. Inactivation of D5,6 desa-
turase (ERG3), an enzyme that acts at an earlier step than
14DM in the ergosterol biosynthesis pathway, results in
altered sterole composition of the membrane (high fecos-
terol content) and fluconazole resistance, possibly by accu-
mulation of 14a-methylfecosterol, which allows growth
[12–14]. Recently it was shown that deletion of the ERG3
gene in C. albicans resulted in reduced susceptibility of the
mutants to fluconazole, providing direct genetic evidence
that alteration of the sterol biosynthesis pathway can cause
fluconazole resistance [15].
3.2. Mutations in the ERG11 gene encoding the drug target
enzyme, 14DM
A frequent cause of drug resistance are mutations in the
target structure that reduce its binding to the drug without
preventing function. To identify alterations in 14DM that
might cause fluconazole resistance, several investigators
compared the sequence of the ERG11 gene of fluconazole-
resistant C. albicans strains with the published ERG11
sequence and that of fluconazole-susceptible strains. As
compared with the published ERG11 sequence, the amino
acid exchanges F105L, E266D, K287R, G448E, G450E,
G464S and V488I were found only in fluconazole-resistant
Fig. 1. DNA fingerprint pattern obtained after Southern hybridization of
EcoRI-digested genomic DNA of C. albicans isolates with the C. albicans-
specific repetitive DNA element CARE-2 [64]. Isolates obtained from
different patients (letters A–G) exhibit different fingerprints. The two
isolates from patient A have an identical fingerprint, the two isolates from
patient D are highly similar and represent subtypes of the same strain.
Patient G harboured three subtypes of the same strain: Isolates G2, G3 and
G6 are identical, isolates G4 and G5 are also identical and differ from the
former by the absence of one band, and isolate G1 exhibits an additional
weak band as compared to G4 and G5.
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isolates, but not in sensitive isolates in one study [16].
However, such sequence differences may simply reflect
allelic variation and by themselves do not prove a causal
relationship with resistance. Similarly, the amino acid
exchanges K128T and K147R were found in sensitive
isolates and were therefore suggested not to cause resist-
ance, but such a conclusion would require a comparison of
the fluconazole susceptibilities of the mutated and an
otherwise identical enzyme. Alterations in the ERG11
sequence in comparison with the published sequence in
fluconazole-resistant isolates were also found by other
investigators [17–19]. In these latter studies it was shown
that the enzymes from the resistant isolates exhibited
reduced sensitivity to inhibition by fluconazole, but the
enzymes exhibited several different amino acid exchanges
and it was not established which were responsible for the
resistant phenotype.
Stronger evidence for mutations in the ERG11 gene
conferring fluconazole resistance was provided by comparing
the sequence of the ERG11 alleles of matched pairs of
fluconazole-susceptible and resistant isolates obtained at
different infection episodes from the same patient. An
R467K mutation was detected in both ERG11 alleles of a
fluconazole-resistant C. albicans isolate as compared with
matched isolates from the same patient with higher sensitivity
[20]. Similarly, a G464S mutation was found in the ERG11
alleles of an isolate displaying enhanced fluconazole resist-
ance from another series of clinical C. albicans isolates [21].
Both amino acids are located near the heme binding site, and
the mutations probably result in structural or functional
alterations associated with the heme. The relationship of
these mutations to the enhanced drug resistance of the strains
was confirmed by the demonstration that higher fluconazole
concentrations were needed to inhibit enzyme activity in cell
free extracts of isolates containing the mutation as compared
with isolates without the mutation [20,21].
A successful approach to demonstrate the involvement of
ERG11 mutations in fluconazole resistance has been the
heterologous expression of different ERG11 alleles in
S. cerevisiae and comparing the susceptibility of the strains
to fluconazole [22]. Since all the variant enzymes were
expressed equally well in the heterologous host, an in-
creased resistance should be due to differences in the amino
acid sequence of the protein. The amino acid exchanges
G129A, Y132H, S405F, G464S and R467K were shown to
cause fluconazole resistance by this approach [22]. Using a
similar strategy, an I471T exchange in ERG11 was also
shown to result in reduced fluconazole susceptibility [23],
and recently an involvement in fluconazole resistance was
demonstrated for additional amino acid exchanges, F126L,
T229A, G307S and F449S [24]. Other mutated ERG11
genes also conferred increased resistance on S. cerevisiae
transformants, but these genes encoded enzymes with multi-
ple amino acid exchanges and it could not be deduced
which of them was responsible for the resistant phenotype
[19,24].
Direct evidence for certain mutations resulting in
decreased affinity to the drug was provided by biochemical
analysis of heterologously expressed enzymes. The affinity
for fluconazole of 14DM containing the mutations Y132H,
G464S or R467K was reduced as compared with the wild-
type enzyme, confirming that these naturally occurring
mutations indeed caused drug resistance in clinical C.
albicans isolates [25–27]. Mutations that should affect
substrate or inhibitor binding can also be inferred from
knowledge of the three-dimensional structure of the
enzyme. Molecular modeling predicted a hydrogen bond
between sterol C3-OH and the threonine at position 315 in
the active center of 14DM. A T315A mutation that was
introduced by design into the C. albicans enzyme indeed
reduced its affinity to fluconazole [28]. The T315A muta-
tion has, however, so far not been found in clinical C.
albicans isolates.
A change from heterozygosity to homozygosity for a
mutated ERG11 gene seems to confer increased resistance.
Such a change was found for clinical isolates with the
G464S or the R467K mutations [20,21]. Genetic evidence
suggests that a cell with two copies of R467K is signifi-
cantly more resistant than a cell in which only one allele has
the mutation [4]. The selection pressure exerted by the
presence of fluconazole seems to favour the conversion to
homozygosity once a mutation conferring enhanced fluco-
nazole resistance has been introduced into one of the ERG11
alleles.
Mutations in the drug target enzyme clearly are an
important mechanism resulting in the emergence of fluco-
nazole-resistant C. albicans strains. Table 1 provides a list of
Table 1
ERG11 mutations causing fluconazole resistance in clinical C. albicans
strains
Mutation Evidence for contribution
to fluconazole resistance
Reference
A B C D
F126L + [24]
G129A + + a [22]
T229A + + [24]
Y132H + + + [22,23,25]
G307S + + [24]
S405F + + [22]
F449S + [24]
G464S + + + + [21,22,24,26]
R467K + + + + [20,22,27]
I471T + [23]
A: Mutation found in a fluconazole-resistant isolate but not in a matched
susceptible isolate from the same patient.
B: Increased fluconazole resistance of enzyme activity in cell-free extracts
of isolates containing the mutation as compared with extracts from matched
isolates without the mutation.
C: Expression of mutated ERG11 gene in S. cerevisiae conferred higher
resistance than otherwise identical gene without the mutation.
D: Biochemical analysis showed reduced affinity of the mutated 14DM for
fluconazole as compared with wild-type enzyme.
a Conferred increased resistance only in combination with the G464S
mutation, but not alone.
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ERG11 mutations that have been found in clinical C.
albicans isolates and whose contribution to fluconazole
resistance has been confirmed by various experimental
approaches. As stated above, more sequence variations have
been found in resistant isolates, but a definite proof for their
involvement in resistance remains to be established. It is
also important to note that the contribution of a mutation to
a resistance phenotype depends on the sequence context of
the particular ERG11 allele in which it occurs, and the
effects of some mutations can be additive [22–24].
3.3. Overexpression of the ERG11 gene
In the presence of fluconazole, C. albicans upregulates
the ERG11 gene, presumably as a feedback mechanism to
make up for ergosterol depletion [21,29]. Franz et al. [21]
reported that even in the absence of fluconazole some
fluconazole-resistant isolates express ERG11 mRNA at
higher levels than matched susceptible isolates in the
presence of the drug. This constitutive ERG11 overexpres-
sion seemed to contribute to fluconazole resistance,
although to a lesser degree than ERG11 mutations, since
twice as much fluconazole was needed to inhibit 14DM
activity in a cell free extract of such a resistant isolate to the
same level as in the extract of a matched susceptible isolate
[21]. ERG11 overexpression has been found in many other
fluconazole-resistant C. albicans isolates compared with
matched susceptible isolates [24,30]. Enhanced gene expres-
sion is expected to result in higher enzyme levels and,
consequently, a need for higher intracellular fluconazole
concentrations to inhibit enzyme activity. There is exper-
imental evidence that such overexpression confers flucona-
zole-resistance. Overexpression of ERG11 from C. albicans
conferred a five-fold enhanced resistance to fluconazole on
S. cerevisiae as compared to transformants carrying the
vector control [28]. When the ERG11 gene was expressed
from doxycyclin-repressible promoters in C. glabrata,
increased levels of ERG11 mRNA correlated with reduced
fluconazole susceptibility [31]. Therefore, constitutive
ERG11 overexpression may contribute to fluconazole resist-
ance in clinical C. albicans strains.
3.4. Overexpression of genes encoding efflux pumps
An important mechanism of fluconazole resistance is
reduced intracellular accumulation of the drug. In recent
years, it became evident that fluconazole is actively trans-
ported out of the cells in an energy-dependent manner and
that an enhanced drug efflux is caused by the overexpres-
sion of genes encoding membrane transport proteins. The
highly homologous genes CDR1 and CDR2 (Candida drug
resistance) encode ATP-binding cassette (ABC) transport-
ers, which use adenosine triphosphate (ATP) as the energy
source, whereas the MDR1 (multidrug resistance) and FLU1
(fluconazole resistance) genes encode major facilitators,
which use the proton gradient across the membrane as the
driving force for transport. The MDR1 gene (originally
termed BENr) had been cloned by its ability to confer
resistance to benomyl and methotrexate upon S. cerevisiae
transformants [32], and its overexpression in S. cerevisiae
was later shown to mediate resistance to a variety of other
drugs [33]. The CDR1 gene is a homolog of the S.
cerevisiae pleiotropic drug resistance gene PDR5 and was
cloned by complementation of the cycloheximide hyper-
sensitivity of an S. cerevisiae pdr5 mutant [34]. Trans-
formants carrying the CDR1 gene displayed increased
resistance to many other drugs, suggesting that CDR1 also
is a multidrug resistance gene. Sanglard et al. [35] demon-
strated that many fluconazole-resistant, clinical C. albicans
isolates displayed strongly increased mRNA levels of CDR1
or MDR1 in comparison with matched susceptible isolates
and accumulated less intracellular fluconazole. They also
showed that S. cerevisiae pdr5 mutants are hypersusceptible
to fluconazole and other azoles and that overexpression of
CDR1 from C. albicans complemented this phenotype,
whereas overexpression of MDR1 restored increased resist-
ance to fluconazole, but not other azoles. Inactivation of
CDR1 in C. albicans itself resulted in enhanced intracellular
fluconazole levels and increased susceptibility of the mutant
to fluconazole and many other drugs, providing genetic
evidence that CDR1 is a multidrug resistance gene in C.
albicans [36]. In contrast, disruption of MDR1 had no effect
on intracellular fluconazole accumulation and did not influ-
ence the susceptibility of the mutants to fluconazole [36,37].
However, the latter result is probably related to the fact that
the strains in which MDR1 had been inactivated, like most
fluconazole-susceptible C. albicans isolates, did not or
barely express MDR1 under the test conditions used
[11,21,29].
The CDR2 gene, which is highly similar to CDR1, was
identified in a screen for C. albicans genes that complement
the hypersusceptibility of S. cerevisiae pdr5 mutants to
azoles [38]. Inactivation of CDR2 in C. albicans had no
effect on intracellular fluconazole accumulation and did not
influence the susceptibility of the mutants to fluconazole,
but this result was probably caused by the absence of CDR2
expression in azole-susceptible C. albicans strains, similar
to what is observed for MDR1 (see above). However,
disruption of CDR2 in a cdr1 mutant background further
increased the susceptibility to fluconazole and other drugs.
Interestingly, derivatives of a cdr1 mutant that regained
wild-type levels of fluconazole-susceptibility expressed the
CDR2 gene, and CDR2 overexpression was also observed in
fluconazole-resistant clinical C. albicans isolates [38].
Therefore, CDR2 encodes a multidrug resistance gene that
can mediate resistance to fluconazole and other drugs in C.
albicans.
The CDR gene family in C. albicans comprises many
more genes, but apart from CDR1 and CDR2 no evidence
for the involvement of other members of the gene family in
fluconazole resistance has been obtained so far [39,40].
Recently, a gene that is homologous to MDR1, FLU1, has
J. Morschha¨user / Biochimica et Biophysica Acta 1587 (2002) 240–248 243
been isolated by its ability to confer fluconazole resistance
on hypersusceptible S. cerevisiae transformants [41]. Inac-
tivation of FLU1 in a C. albicans strain in which several
other multidrug resistance genes had been deleted resulted
in increased susceptibility to fluconazole, demonstrating that
FLU1 can mediate fluconazole resistance in C. albicans.
However, overexpression of FLU1 has not yet been found
as a cause of fluconazole resistance in clinical C. albicans
isolates.
Overexpression of efflux pumps encoded by the CDR1,
CDR2 and MDR1 genes has been shown to be one of the
most frequent mechanisms of fluconazole resistance
[8,11,21,24,30,35,38,42,43], but the exact mechanism how
resistance is mediated has not been resolved, nor is the
physiological function of these membrane transport proteins
known. Recent studies suggested that Cdr1p transports
phospholipids from the inner to the outer leaflet of the
cytoplasmic membrane, thereby changing the membrane
structure [44]. Earlier studies had demonstrated that reduced
intracellular fluconazole accumulation was associated with
an altered membrane structure, presumably resulting in
reduced drug uptake [45]. The resistance phenotype asso-
ciated with overexpression of membrane transport proteins
may therefore not only be caused by enhanced efflux, but
could in part also be due to membrane alterations resulting
in reduced drug uptake, a possibility that has not been
investigated so far and should be kept in mind.
3.5. Multiple mechanisms contribute to a stepwise develop-
ment of fluconazole resistance in C. albicans
Each of the mechanisms described above can cause
reduced susceptibility of C. albicans to fluconazole. Several
studies have shown that multiple mechanisms may be
combined to result in a stepwise development of fluconazole
resistance, which ultimately becomes clinically relevant and
causes therapy failure. For example, White [30] described
gradual increases in fluconazole resistance in serial isolates
of a C. albicans strain by overexpression of MDR1, ERG11,
and one or more of the CDR genes, combined with the
aquisition of the R467K mutation in ERG11. Sanglard et al.
[22] found different combinations of ERG11 mutations with
overexpression of MDR1, CDR1 or CDR2, in other series of
C. albicans isolates, and Franz et al. [21] reported two series
of clinical C. albicans isolates in which MDR1 overexpres-
sion was combined with either the G464S mutation or
ERG11 overexpression. Combinations of different resistance
mechanisms have recently been reported to be responsible
for fluconazole resistance in the majority of clinical C.
albicans strains studied [24]. It is therefore evident that
the generation of a highly resistant strain from a highly
susceptible strain is the result of multiple mechanisms, each
of which contributes only partially to the resistant pheno-
type. Whether a particular alteration creates a clinically
resistant C. albicans strain therefore depends on the genetic
background in which this alteration occured, i.e. if the strain
already exhibited other mutations resulting in decreased
susceptibility, even when the previous changes did not cause
a clinically relevant resistance level. For example, some
ERG11 mutations which have been shown experimentally to
cause fluconazole resistance have also been found in iso-
lates with MICs in the susceptible range [24], and the
overexpression of genes encoding efflux pumps is not
necessarily sufficient to result in clinically relevant resis-
tance.
4. The regulation and role of the MDR1 gene in C.
albicans fluconazole resistance
In the presence of fluconazole, C. albicans induces
expression of the ERG11 gene above its normal level,
presumably in response to ergosterol limitation [21,29]. In
contrast, the genes encoding efflux pumps, MDR1, CDR1
and CDR2, are not activated under same conditions [21,29].
However, in many fluconazole-resistant clinical C. albicans
isolates, these genes are constitutively overexpressed, indi-
cating that mutations must have occurred in these strains
that abolish the normal regulation of the genes. Such
mutations could either occur in the promoter region of the
genes themselves or involve trans-regulatory factors. The
comparison of the promoter sequences of bothMDR1 alleles
of two matched pairs of clinical C. albicans isolates in
which fluconazole resistance correlated with constitutitve
MDR1 expression did not reveal promoter mutations that
might be responsible for MDR1 activation in the resistant
isolates [46]. Direct evidence for the involvement of an
altered regulatory factor was obtained by integrating a green
fluorescent protein (GFP) reporter gene under the control of
Fig. 2. Minimal inhibitory concentration of fluconazole for the fluconazole-
susceptible C. albicans isolates F2 and G2, the matched resistant isolates F5
and G5, and the heterozygous (F5M402 and G5M402) and homozygous
(F5M432 and G5M432) mdr1 mutants derived from the resistant isolates.
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the MDR1 promoter from a fluconazole-susceptible C.
albicans strain at an ectopic site into the genome of the
two matched pairs of clinical isolates. Although the MDR1
promoter controlling GFP expression was identical in all
four reporter strains, only the fluconazole-resistant isolates,
but not the matched susceptible isolates, expressed the GFP
[46]. Therefore, the activation of the MDR1 gene in these
fluconazole-resistant isolates must have been caused by
mutations in regulatory factors, and this is likely to be true
also for other fluconazole-resistant C. albicans isolates and
other genes encoding efflux pumps. Several C. albicans
genes encoding regulatory factors that influence the expres-
sion of efflux pumps have been identified, for example the
CAP1 gene, which is homologous to YAP1 from S. cerevi-
siae, or the FCR1, FCR2 and FCR3 genes [47–49]. How-
ever, there is no evidence so far for these transcriptional
regulators being the cause of the constitutive overexpression
of efflux pumps in clinical C. albicans strains.
The involvement of regulatory factors in MDR1 over-
expression pointed to the possibility of a simultaneous
activation of additional genes, including genes encoding
yet unknown efflux pumps. Therefore, the activation of
other genes than MDR1 might be the cause of fluconazole
resistance. In fact, MDR1 disruption in C. albicans labo-
ratory strains did not enhance the susceptibility of the
mutants to fluconazole [36,37]. However, these strains did
not detectably express the MDR1 in vitro and, as noted
above, fluconazole also does not induce MDR1 expression
in C. albicans. To assess the contribution of MDR1 over-
expression to fluconazole resistance, it was therefore neces-
sary to inactivate the gene in fluconazole-resistant, clinical
C. albicans isolates. Until recently, the gene disruption
Fig. 3. Susceptibility of the matched fluconazole-susceptible and resistant clinical C. albicans isolate pairs (F2/F5 and G2/G5) and the mdr1 null mutants
F5M432 and G5M432 derived from the resistant isolates F5 and G5, respectively, to other drugs. The enhanced resistance of isolates F5 and G5, as compared
with F2 and G2, to 4-NQO, cerulenin, and brefeldin A is due to MDR1 overexpression, because it is abolished by deletion of the MDR1 gene. The slightly
increased resistance of F5 and G5 to amorolfine and terbinafine was not affected by MDR1 deletion, and therefore, must have been caused by other genomic
alterations than MDR1 overexpression. The susceptibilities of the strains to fluphenazine and benomyl remained unchanged by either MDR1 overexpression or
deletion of the gene in the MDR1 overexpressing isolates.
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approach in C. albicans was confined to auxotrophic ura3
mutants, but could not conveniently be performed in wild-
type strains [50]. The development of a mutagenesis proce-
dure that is based on the use of a recyclable, dominant
selection marker allowed targeted gene inactivation also in
clinical C. albicans isolates [51]. Disruption of the MDR1
gene in two different, MDR1 overexpressing C. albicans
isolates resulted in enhanced susceptibility of the mutants to
fluconazole, providing direct genetic evidence that MDR1
overexpression contributes to fluconazole resistance in clin-
ical C. albicans isolates [51] (Fig. 2).
5. MDR1 overexpression mediates multidrug resistance
in C. albicans
The results of experiments in which MDR1 overexpres-
sion in hypersusceptible S. cerevisiae strains conferred
resistance to a variety of structurally unrelated drugs in
addition to fluconazole suggested that Mdr1p transports
many different toxic substances. Consequently, deletion of
the MDR1 gene in a C. albicans strain that expressed high
MDR1 mRNA levels resulted in an enhanced susceptibility
of the mutant to several of these drugs [52]. Interestingly,
however, mdr1 deletion in this strain had no effect on the
susceptibility to benomyl, a drug that was thought to be an
Mdr1p substrate from the heterologous expression studies.
This result was interpreted as C. albicans having other
resistance mechanisms, presumably efflux systems that
compensate for the loss of the MDR1 gene. Clinical C.
albicans isolates which overexpressed MDR1 were also
more resistant to other drugs in addition to fluconazole,
e.g. 4-nitroquinoline-N-oxide (4-NQO), cerulenin, and bre-
feldin A, as compared with matched isolates that did not
detectably express MDR1 in vitro [53] (Fig. 3). The
increased resistance was abolished when the MDR1 gene
was deleted from the genome of these isolates, providing
genetic evidence that MDR1 overexpression in clinical C.
albicans isolates indeed confers resistance to various, struc-
turally unrelated drugs [53]. However, MDR1 overexpres-
sion in such clinical isolates did not enhance resistance to
some other drugs that were thought to be Mdr1p substrates,
e.g. amorolfine, terbinafine, fluphenazine and benomyl, and
MDR1 deletion did not influence the susceptibility of the
strains to these drugs (Fig. 3). Even if C. albicans possesses
other mechanisms of resistance to these toxic compounds
one would expect that, if Mdr1p can transport these sub-
stances out of the cell, a strong overexpression of MDR1
should further increase resistance, similar to its contribution
to fluconazole resistance, which is often mediated by several
additive mechanisms. These findings, together with the
absence of an effect of MDR1 deletion, suggests that
heterologous expression studies may in some cases give
misleading results about the substrate spectrum of the efflux
pumps in C. albicans. The expression of C. albicans
membrane proteins in S. cerevisiae host strains may alter
the structure of the cell membrane, especially in strains in
which one or several of their own genes encoding mem-
brane proteins were deleted, and these alterations might
indirectly influence the susceptibility of the cells to toxic
compounds. As mentioned above, such alterations in mem-
brane structure have been observed after overexpression of
the CDR1 gene in S. cerevisiae [44]. It should also be noted
that no direct proof has yet been provided that the C.
albicans efflux pumps bind and transport antifungal drugs.
Whatever the mechanism is, there is now convincing
evidence that the overexpression of MDR1, and also the
CDR1 and CDR2 genes, contributes to the fluconazole-
resistant phenotype of clinical C. albicans isolates.
6. Conclusions and perspectives
Considerable efforts have been undertaken in the past
years to unravel the molecular mechanisms of fluconazole
resistance in C. albicans, and this knowledge should help to
devise strategies to overcome the resistance problem. Muta-
tions resulting in reduced affinity of the target enzyme
14DM to fluconazole have been uncovered, but the precise
way how the amino acid exchanges influence the binding of
the drug can only be fully understood when more structural
information on wild-type and mutated enzymes becomes
available. This information may allow the design of drug
derivatives whose binding is not affected by the resistance
mutations.
The development of efflux pump inhibitors that could be
used in combination with fluconazole is a promising strat-
egy to abolish resistance of strains overexpressing these
transporters [54]. Interestingly, S. cerevisiae transformants
expressing CDR1 from C. albicans exhibited increased
sensitivity to peptidic antifungals and other drugs [34,55].
Although similar findings have not been reported for CDR1
overexpressing C. albicans, these observations suggest that
the development of drug resistance may also create new
vulnerable sites which may be exploited to preferentially
attack fluconazole-resistant strains. The mutations respon-
sible for overexpression of the genes encoding efflux pumps
in fluconazole-resistant clinical C. albicans isolates are still
unknown, but presumably involve alterations in regulatory
proteins [46]. The elucidation of the regulatory pathways
controlling expression of these genes may provide a ration-
ale basis for approaches to interfere with their activation and
thus overcome resistance.
Mutations resulting in drug resistance provide a selective
advantage in the presence of the drug. However, some of the
described alterations might reduce the fitness of the resistant
strains under non-selective conditions, for example ERG11
mutations that also lower 14DM activity [26,27] or the
unregulated expression of genes encoding efflux pumps,
which is tightly controlled in the parental strains [46]. Some
fluconazole-resistant isolates in fact exhibit reduced viru-
lence, but virulence may also remain unaltered or even be
J. Morschha¨user / Biochimica et Biophysica Acta 1587 (2002) 240–248246
increased [56,57]. Fluconazole-resistant strains can loose
the resistant phenotype during propagation in drug-free
medium, arguing for a selective disadvantage of some
resistance mutations [42]. On the other hand, it was recently
also demonstrated that the costs of resistance can be over-
come during further evolution of in vitro generated fluco-
nazole-resistant C. albicans strains [58]. It will be
interesting to test whether clinical C. albicans having differ-
ent resistance mutations may display a reduced fitness as
compared with their drug-sensitive parents within the com-
plex environment of the host. Adequate treatment strategies
might reduce the frequency of resistant strains [59]. An
important research area also is the intrinsic resistance of C.
albicans to fluconazole when the organism grows as a
biofilm [60–62]. The basis of biofilm resistance, which
seems to be independent of the expression of efflux pumps
[63], and its implications for the treatment of Candida
infections remain to be elucidated.
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